Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Zydus Cadila today said it is looking for partnership to market its new chemical entity (NCE) Lipaglyn, to be used for treating a type of diabetes in developed and developing markets. "Lipaglyn is the first glitazar to be approved in the world and the first NCE discovered and developed indigenously by an Indian pharma company. The new drug is expected to be launched in Q3 of this fiscal in the country," Zydus Cadila Chairman and Manging Director Pankaj Patel told reporters. The company has spent USD 250 million in developing Lipaglyn and aims to spend another USD 150-200 million to launch the drug in overseas markets in next 3-5 years period, Patel said, adding that the company is looking for marketing partnerships.
Help employers find you! Check out all the jobs and post your resume.
Zydus Cadila today said it is looking for partnership to market its new chemical entity (NCE) Lipaglyn, to be used for treating a type of diabetes in developed and developing markets. "Lipaglyn is the first glitazar to be approved in the world and the first NCE discovered and developed indigenously by an Indian pharma company. The new drug is expected to be launched in Q3 of this fiscal in the country," Zydus Cadila Chairman and Manging Director Pankaj Patel told reporters. The company has spent USD 250 million in developing Lipaglyn and aims to spend another USD 150-200 million to launch the drug in overseas markets in next 3-5 years period, Patel said, adding that the company is looking for marketing partnerships.
Help employers find you! Check out all the jobs and post your resume.
